Mesenchymal stem cell transplantation can regulate neuroinflammation and treat Alzheimer's disease (AD), but its effect is attenuated by in vitro expansion. To solve this problem, we used tanshinone IIA (TIIA)-incubated mesenchymal stem cells (MSCs) to treat neuroinflammation caused by amyloid β-protein (Aβ). Here, we demonstrated that behavioral performance was rescued in rats receiving an intracerebroventricular injection of TIIA-incubated MSCs (TIIA-MSCs), and the TIIA-MSCs protected against neurotoxicity in the rat hippocampus by suppressing Aβ 25-35 -induced neuroinflammation. The levels of interleukin-1 (IL-1), IL-4, IL-6, IL-10 and tumor necrosis factor α (TNF-α) in Aβ 25-35 -induced rats were attenuated by TIIA-MSCs treatment, and IL-6 was the key difference between the TIIA-MSCs and MSCs groups. Furthermore, TIIA-MSCs reduced Aβ production-related mRNA (BACE1 and PS1) expression but had no significant effect on clearance (AMDM10). TIIA-MSCs also had the same effects on the protein levels. For the first time, we found that TIIA-MSCs have greater neuroprotective effects and prevent toxic protein production better than MSCs. These effects are related to Aβ modulation via downregulated BACE1 expression that promotes the survival of hippocampal neurons, as well as regulates neuroinflammatory-associated cytokines. These results provide support for the clinical application of MSCs, which will bring new hope for the treatment of AD.
Introduction
Currently, the aging population of the world has exceeded 11%, and we have entered the era of aging societies [1] . With the occurrence of an aging society, the incidence of neurodegenerative diseases, mainly Alzheimer's disease (AD), increases yearly [2] . Studies have shown that misfolded and precipitated proteins can activate neuroinflammation, and abnormally activated neuroinflammatory responses are important causes of the progressive exacerbation and progression of AD [3] . As early as 1982, inflammation-related proteins, complement factors, and immunoglobulins were found in the senile plaques of AD patients [4] . Therefore, effective control of this neuroinflammation may be an efficacious method for treating AD. With the rapid development of modern biotechnology, mesenchymal stem cells (MSCs) transplantation has become a new potential treatment for AD neuroinflammation. MSCs were originally found in bone marrow and are pluripotent stem cells derived from mesoderm that differentiates into specific mature cells (neural, bone, myocardium, etc.) under specific environmental stimuli [5, 6] . These cells can be ideal seed cells for restoration in regenerative medicine [7] . Notably, MSCs have strong immunomodulatory abilities and show effective regulation in different inflammatory conditions. In the case of weak inflammation, these cells can promote the immune response; when the inflammatory response is strong, they can suppress the immune response and ultimately maintain the inflammatory immune response in the body within a reasonable range [8] . In addition, some researchers have found that MSCs have advantages that other stem cells do not. Among stem cells, only MSCs can migrate toward damaged tissues. Due to their plasticity and ability to migrate toward damaged tissues, MSCs have good application prospects for anti-AD neuroinflammation treatments [9] .
However, the application of MSCs still faces problems and challenges [10] . One issue is MSCs cell death after in vitro expansion. In this situation, the ability to differentiate into specific mature cells according to the environment is weakened, as well as the ability to regulate inflammation. Therefore, the identification of a method to address this problem after in vitro expansion is needed. Tanshinone IIA (TIIA) is a biologically active component isolated from the traditional Chinese medicine Salvia miltiorrhiza [11] . In recent years, MSCs differentiation has been induced in specific environments [12] . Therefore, the use of TIIA for the preparation of MSCs may prevent the deficiencies and defects of MSCs in the treatment of AD neuroinflammation. 
Materials and methods
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MSCs and TIIA treatment
Briefly, cells were flushed from the tibia bones of donor rats and placed in DMEM/F12 containing 15% FBS and 1% penicillin/streptomycin at a cell concentration of 10 6 /ml in a 25-cm 2 culture flask. The cells were incubated in 5% CO 2 at 37°C, and the medium was replaced every 2 days. The primary culture was 1-2 passages at 80%∼90% confluence. The MSCs from the third passage were used in this study. MSCs were analyzed after the third passage by flow cytometry according to routine protocols. Briefly, cell suspensions (3∼5 × 10 5 / tube) were incubated with monoclonal antibody (1:100 dilution) for 1 h in the dark, washed three times with PBS, and then analyzed using a FACSCalibur™ system (BD Immunocytometry Systems, San Jose, CA). The antibodies used in the experiments were FITC-CD24, FITC-CD34, and FITC-CD90. At the second passage, some MSCs were incubated with TIIA (10 μM) for 48 h to obtain TIIA-incubated MSCs. TIIA (10 μM) was prepared with complete medium.
Animals and grouping
Four-week-old male Sprague Dawley (SD) rats (weighing 160∼200 g) and 6-month-old male SD rats (230∼250 g) were obtained from the Experimental Animal 
Aβ injections and surgery
Rats were anesthetized with 10% chloral hydrate (0.3 mL/100 g) and fixed on a rat brain stereotaxic apparatus after anesthesia. The needle in the hippocampus was at AP-4 mm (front and posterior), MLR-2.8 mm (left and right of the midline), and H-3 mm (depth from the meninges). After positioning, the skull was drilled, the microinjector was inserted vertically 3 mm, and 2 μl of Aβ 25-35 (10 μg) was slowly injected at a rate of 0.2 μl/min with the needle left in place for 5 min. The sham operation group was injected with an equal volume of solvent into the corresponding brain area. One week after the model was established, MSCs were transplanted, and 5 μl (5 × 10 5 ) of the cells was injected into the left and right hippocampus in the same manner as in the modeling, and the other groups were injected with the same amount of DMEM/F12.
Morris water maze task
Spatial memory function was assessed using the Morris water maze (MWM) task. The water maze test equipment consisted of a platform, camera and black circular pool (80-cm radius and 50-cm depth). The pool was artificially divided into four quadrants with four start positions: I, II, III, and VI. As described in our previous study, the escape platform was placed randomly in one of the quadrants during the experiment [13] . The swimming activity of each rat was recorded by a video camera and analyzed by a tracking software system. The test was divided into two parts: the acquisition trial and the probe trial. The acquisition trial was used to evaluate the learning ability of the rats. The learning and memory function of the rats was observed from day 11 after Aβ 25-35 injection, and the rats were placed into the maze from the four quadrants of the maze and trained for 5 consecutive days. The escape latency was defined as the time required to locate the escape platform within 120 s. The rats were allowed to rest for 60 s after they located the platform. If the rat was unable to find the platform within 120 s, it was guided to the platform and allowed to rest for 60 s. The escape latency was recorded as 120 s in these cases. The probe trial was conducted on the 6th day after removing the platform to test the spatial memory capacity. The time the rat spent in the target quadrant and the number of times crossing the platform were recorded and described as the spatial memory. The data were analyzed by observers who were blinded to the experimental treatment groups.
Hematoxylin-eosin (HE) staining
Brains were fixed in paraformaldehyde for a week, sliced across the region of the hippocampus (Leica CM 1850 UV; Leica, Nussloch, Germany), and embedded in paraffin; 4-μm sections were used for regular HE staining according to the manufacturer's protocol. Morphological changes in the CA3 region of the hippocampus were observed by light microscopy (BX43, Olympus, Japan).
Quantitative RT-PCR
The experiments were conducted according to routine protocols. Total RNA from cells was extracted using TRIzol reagent, and cDNA was synthesized using a cDNA synthesis kit. Target genes were amplified from the synthesized cDNA, and the samples were subjected to agarose gel electrophoresis. The target gene intensity on the gel was then quantified by densitometry. The relative gene expression level was normalized to the GAPDH transcript level. Each value represents the average of three independent experiments. Reactions were carried out at 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. The following primers were used for target gene amplification: (Table 1) .
ELISA
The levels of neurotransmitters (ACh, ACHE) and inflammatory factors (IL-1, IL-4, IL-6, IL-10, TNF-α) of rats were detected using an ELISA kit according to the manufacturer's protocol. Approximately 30 mg of tissue was cut on dry ice, and 500 μl of PBS was added. The sample was ground on ice until there was no obvious precipitation. The sample was centrifuged at 12,000 rpm for 10 min at 4℃, and the supernatant was collected. Part of the centrifuged supernatant was used for protein quantification. The protein concentration was diluted to the detection range of the kit. Then, the absorbance of the samples was measured at 450 nm using a microplate reader (Multiskan™ GO, Thermo Scientific™, USA).
Western blot analysis
Briefly, rat tissues were homogenized and lysed in RIPA lysis buffer supplemented with the proteinase inhibitor PMSF and a 1× phosphatase inhibitor cocktail. The lysates were treated on ice for 30 min and centrifuged at 14,000 g for 15 min. The supernatants were acquired, and whole protein levels were quantified using a BCA assay kit. Equal amounts of total protein (30 μg) were used per lane, and the lysates were separated using 8-12% SDS-PAGE and transferred onto PVDF membranes. After the membranes were blocked with 5% nonfat milk in TBST (0.1% Tween 20) at room temperature for 1 h, they were incubated with specific primary and secondary antibodies. The proteinantibody complexes were visualized using ECL reagent. The intensities of the bands were quantitated with Quantity One software version 4.6.1 (Bio-Rad, USA).
Statistical analysis
All experiments were repeated three or more times. All data in this study are expressed as the mean ± S.E.M. Statistical significance was determined with analysis of variance (ANOVA) followed by least significant difference (LSD) post hoc tests using SPSS 22.0 software. P < 0.05 was regarded as statistically significant. All figures were created using GraphPad Prism 7 (GraphPad Software, La Jolla, CA) and Adobe Illustrator CS6 (Adobe, San Jose, CA).
Results
General condition of the rats
Some rats died during the operation and postoperative period, but no differences in mortality among the groups were observed (P > 0.05). There were no differences in body weight among the groups, suggesting that modeling and administration did not affect the growth of the rats.
Identification of MSCs
Flow cytometric analysis showed that the cells were negative for CD34 but positive for the CD24 and CD90 markers (Fig. 2). 
Effects of TIIA-MSCs on the learning and memory impairment induced by Aβ 25-35 in rats
After Aβ 25-35 and/or TIIA-MSCs administration, the spatial learning and memory performances of rats were assessed by the MWM test. As shown in Fig. 3A , a repeated-measure ANOVA revealed a significant difference in the escape latency among the control, model, MSCs and TIIA-MSCs groups. The escape latency of each group decreased with time, and significant differences between the groups appeared on the 4th day of detection. The escape latency of the model group was longer than that of the control group, while that of the TIIA-MSCs group rats was significantly decreased. Interestingly, there was no significant difference in the escape latency between the MSCs group and the model group. At the same time, in the probe trial on the 5th day, there were no significant differences in either the percentage of time spent in the target quadrant (Fig. 3B) or the target quadrant frequency (Fig. 3C ). No differences were observed for the swimming speeds among all the groups (Fig. 3D) , suggesting that TIIA-MSCs and Aβ 25-35 did not affect the motor functions of rats. Taken together, these data indicated that TIIA-MSCs might ameliorate Aβ 25-35 -induced spatial learning and memory impairments in rats and are superior to MSCs.
A. Escape latency; B. percentage of time spent in the target quadrant (%); C. target quadrant frequency; D. swimming speed. (mean ± SEM, n = 10-12) * P < 0.05 vs the control group, # P < 0.05 vs the model group. 
Effect of TIIA-MSCs on Aβ 25-35 -induced hippocampal neuronal injury in rats
We observed the morphology of rat hippocampal neurons by HE staining (Fig. 4) . HE staining showed unhealthy neurons in the CA3 region of the hippocampus of the model group; most neurons appeared indistinct, lacked a clear cell boundary and had a small darkened nucleus. In contrast, few unhealthy cells were observed in the TIIA-MSCs groups compared with the model group. The hippocampal neuron morphology of the TIIA-MSCs group was closer to that of the control group than that of the MSCs group.
Effects of TIIA-MSCs on mRNA expression in Aβ 25-35 -induced rats
As shown in Fig. 5 , the mRNA expression of hippocampal APP was higher in Aβ 25-35 -induced rats than in control rats (Fig. 5A ), but this mRNA expression was attenuated by TIIA-MSCs or MSCs treatment compared with that in Aβ 25-35 -induced rats. At the same time, the mRNA expression of AMDM10 did not change significantly among the groups (Fig. 5B) . Interestingly, the mRNA expression of BACE1 and PS1 was similar to that of APP (Fig. 5C, D) , but there was a significant difference between the MSCs and the TIIA-MSCs groups.
A. Aβ mRNA expression; B. AMDM10 mRNA expression; C. BACE1 mRNA expression; D. PS1 mRNA expression (mean ± SEM, n = 3).
Effects of TIIA-MSCs on cytokines and neurotransmitters in the hippocampus of Aβ 25-35 -induced rats
IL-1, IL-4, IL-6, IL-10 and TNF-α are important cytokines involved in neuroinflammation. As shown in Fig. 6 , the levels of IL-1, IL-4, IL-10 and TNF-α in the hippocampus were higher in Aβ 25-35 -induced rats than in control rats (Fig. 6A, B, C, D) ; however, these levels were attenuated by TIIA-MSCs or MSCs treatment compared with those in Aβ 25-35 -induced rats. Furthermore, the level of IL-6 (Fig. 6E ) was similar to that of IL-1, but the IL-6 levels were not significantly different between the MSCs group and the model group. ACh is a neurotransmitter that is rapidly destroyed by ACHE in the body. As shown in Fig. 7F , the level of ACh in the hippocampus was lower in Aβ 25-35 -induced control rats and higher after TIIA-MSCs treatment than in Aβ 25-35 -induced rats. In addition, there was a significant difference between Fig. 2 . Confirmation of MSCs isolated from tibia bones of donor rats by flow cytometry. Isolated MSCs were positive for CD24 and CD90 but negative for CD34 (a marker of hematopoietic cells). the MSCs and TIIA-MSCs groups. As shown in Fig. 6G , the level of hippocampal ACHE was higher in Aβ 25-35 -induced rats than in control rats, and this effect was attenuated with TIIA-MSCs treatment compared with that in Aβ 25-35 -induced rats. Hippocampal ACHE levels were not significantly different between the MSCs group and the model group.
Effects of TIIA-MSCs on the protein levels of AMDM10, BACE1, PS1
and Aβ in the hippocampus of Aβ 25-35 -induced rats
To investigate the Aβ changes induced by TIIA-MSCs in the Aβ 25-35 -induced neuronal injury model, we assessed several proteins involved in peptide production and removal pathways. Compared with those of the control group, the levels of Aβ 1-40 , BACE1 and PS1 in the model group increased, while the levels in the TIIA-MSCs group decreased compared with those in the model group (Fig. 7B, D, E) . Interestingly, there was a significant difference between the MSCs and TIIA-MSCs groups with respect to Aβ 1-40 and BACE1 (Fig. 7B, D) , while the MSCs group did not show significant differences compared to the model group (Fig. 7E) . At the same time, the level of AMDM10 did not change significantly among the groups (Fig. 7C ).
Discussion
AD is a complex neurodegenerative disease. Although scientists have proposed many theories to explain the pathogenesis of AD, each hypothesis has various shortcomings [14] . Regardless of whether AD is initiated by external environmental factors or internal genetic factors, all the pathogenic characteristics of AD are accompanied by inflammation, and inflammation plays an important role throughout the pathological process of AD [3] . Early moderate inflammation can remove harmful proteins, which is beneficial for the brain, but with age, the barrier function of the blood-brain barrier declines, and increased levels of harmful foreign substances enter the brain. In cases involving mutations, inflammation will continue to aggravate the symptoms, forming a vicious cycle due to the accumulation of toxic proteins [15, 16] . With the progressive increase in damage, related signal N. Huang, et al. Behavioural Brain Research 365 (2019) [48] [49] [50] [51] [52] [53] [54] [55] regulatory pathways further inhibit the inflammatory factors damaging the nerve cells. Eventually, these changes will result in neuronal degeneration, which is the basis of behavioral memory abnormalities [15] . Therefore, as the disease progresses, AD patients will gradually display behavioral memory abnormalities, which eventually increase. Effective control of this vicious cycle of inflammatory responses in the brain may not cure AD, but it can effectively delay the exacerbation of the illness and maximize patient quality of life. MSCs are most notable for their strong immunomodulatory capacity and their remarkable ability to regulate various inflammatory conditions in the body. In the case of weak inflammation, these cells can promote immune responses; in the case of a strong inflammatory response, they can suppress the immune response and ultimately maintain the body's inflammatory immune response in a reasonable range [8] . Thus, MSCs have a biphasic regulatory capacity generally superior to that of NSAIDs. As Hegel argued in the "Principles of Jurisprudence", it is reasonable that the presence of neuroinflammation is significant, and neither simple inhibition nor neuroinflammation is the best solution. However, the clinical application of MSCs faces many problems, especially the ability of MSCs to differentiate into specific mature cells according to the environment after in vitro expansion is reduced and aging occurs [10] . Therefore, we used TIIA for the preparation of MSCs to determine whether this treatment can overcome the shortcomings and defects of MSCs in the neuroinflammation of AD.
Our results showed that under experimental conditions, the escape latency of the model group was longer than that of the control group, while that of the TIIA-MSCs group rats was significantly shortened. Interestingly, there was no significant difference in escape latency between the MSCs group and the model group. Both the percentage of time spent in the target quadrant and the target quadrant frequency showed significant differences. TIIA-MSCs ameliorated Aβ 25-35 -induced spatial learning and memory impairments in rats and were superior to MSCs. As noted earlier, the most direct reason for the decline in learning and memory is neuronal changes; therefore, we investigated the cause in this study. We observed the morphology of rat hippocampal neurons by HE staining, and the hippocampal neuron morphology of the TIIA-MSCs group was closer to that of the control group than that of the MSCs group. The traditional function of neurons is closely related to the number of neurotransmitters. In this study, ACh increased significantly, while ACHE decreased, indicating that the signal transmission between nerves was restored to a certain extent. These indicators showed that our treatment is indeed pharmacodynamically useful. Then, we further explored the possible underlying mechanism. In cases of mutations, inflammation will continue to aggravate the condition, forming a vicious cycle with the accumulation of toxic proteins [3, 15] . Therefore, we examined the level of cytokines in rats and found that protein toxicity was decreased significantly in this experiment. The levels of IL-1, IL-4, IL-10 and TNF-α in the hippocampus were increased in Aβ 25-35 -induced rats relative to those in control rats and were attenuated by TIIA-MSCs or MSCs treatment compared with those in Aβ 25-35 -induced rats. Moreover, the level of IL-6 was the key difference between the TIIA-MSCs and MSCs groups. Next, we were interested in how these changes affected the formation of toxic proteins.
Therefore, we initially explored the possible regulatory mechanisms. Aβ is produced by the metabolism of APP [17] . There are two metabolic pathways of APP: one is the non-amyloid pathway in which normal physiological APP is metabolized. APP is metabolized mainly by α-secretase and γ-secretase to produce CTF-γ and nontoxic P3 fragments. This metabolic pathway does not produce Aβ, and the sAPPα product also has neuroprotective effects; the second is the amyloidproducing pathway, and APP is acted on by β-secretase and γ-secretase to produce CTF-γ and toxic Aβ fragments [18] [19] [20] . Thus, α, β and γ-secretases play a key role in the processing of APP. Analysis of the mRNA expression of APP, AMDM10, BACE1 and PS1 showed that TIIAMSCs reduced Aβ production-related mRNA (BACE1 and PS1) expression but had no significant effect on clearance (AMDM10). At the same time, the protein levels showed the same effect as TIIA-MSCs. TIIAMSCs have stronger neuroprotective and toxic protein production than MSCs, which is related to its regulation of BACE1 and PS1, especially the regulation of BACE1.
Conclusion
In summary, the present study demonstrated that TIIA-MSCs significantly improved learning and memory in rats administered Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and were more effective than MSCs. The protective mechanisms are likely due to Aβ modulation via the downregulation of BACE1 expression to promote the survival of hippocampal neurons, as well as the regulation of neuroinflammatory-associated cytokines. Although the mechanism of how neuroinflammation affects toxic proteins in this study remains unclear, these results will provide more support for the clinical application of MSCs, which will bring new hope for the treatment of AD.
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